Press release
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 ZUG, Switzerland, September 6, 2023 – MoonLake Immunotherapeutics AG
About this update from Moonlake Immunotherapeutics
[{"type":"text","content":"MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 ZUG, Switzerland, September 6, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Day for investors and analysts on Monday, September 11. The live webcast will be viewable from 11:30 am – 13:00 pm EDT/16:30 pm – 18:00 BST/17:30 – 19:00 pm CEST. Registration for the webcast is open and accessible online here. The MoonLake team will discuss the evolving psoriatic arthritis (PsA) market and expectations ahead of the top-line 12-week results from the Phase 2 ARGO trial which is expected in the first half of November 2023. Following the positive top-line 12-week results from the Phase 2 MIRA trial in hidradenitis suppurativa (HS) announced in June, the team will also summarize focus areas for the anticipated 24-week data readout, which is expected in mid-October 2023. In addition, the event will feature a presentation from external speaker Joseph F. Merola, MD, MMSc, Associate Professor at Harvard Medical School, Vice Chair of Clinical Trials and Innovation and Director of the Center for Skin and Related Musculoskeletal Diseases in the Department of Dermatology and Department of Medicine, Division of Rheumatology at the Brigham and Women’s Hospital in Boston, Massachusetts. A Q&A session will follow the presentations. Additional details will be available on the Events & Presentations section of the Company’s website at www.ir.moonlaketx.com. - Ends - About MoonLake Immunotherapeutics MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at www.moonlaketx.com. About Nanobodies® Nano...